Literature DB >> 15290744

Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently.

Rebecca L Robinson1, Howard G Birnbaum, Melissa A Morley, Tamar Sisitsky, Paul E Greenberg, Frederick Wolfe.   

Abstract

OBJECTIVE: Depression and fibromyalgia (FM) are often coincident. Both syndromes share common symptoms and impose significant economic burdens. This study compared claims for treatment and costs of FM plus depression with those for FM or depression alone.
METHODS: Administrative claims data from a national Fortune 100 manufacturer were used to identify 3 mutually exclusive patient cohorts based on claims with a diagnosis for: FM only, depression only, and FM plus depression. A fourth cohort comprised a random sample of 10% of the employer's overall beneficiary population. Cohorts were compared for demographics, comorbid conditions, and healthcare resources utilization. Mean direct (treatment) costs were calculated and indirect (work loss) costs imputed, and these were assessed using Student's t test and Bonferroni adjustments.
RESULTS: Mean annual employer payments (direct plus indirect costs) per patient were 5,163 dollars for FM only, 8,073 dollars for depression only, 11,899 dollars for FM plus depression, and 2,486 dollars for the overall sample. Mean incremental employer payments (i.e., above those for the random sample) per patient with FM plus depression were 9,413 dollars, an amount more than the sum of incremental costs for those with FM or depression alone (8,264 dollars). These costs are consistent with costs of other chronic diseases.
CONCLUSION: Patients with FM plus depression are high users of healthcare services. As in studies that established relationships between depression and other medical conditions, incremental costs for patients with FM plus depression were more than additive of costs for each condition alone.

Entities:  

Mesh:

Year:  2004        PMID: 15290744

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  [Definition, classification and diagnosis of fibromyalgia syndrome].

Authors:  W Eich; W Häuser; E Friedel; A Klement; M Herrmann; F Petzke; M Offenbächer; M Schiltenwolf; C Sommer; T Tölle; P Henningsen
Journal:  Schmerz       Date:  2008-06       Impact factor: 1.107

Review 2.  Fibromyalgia: disease synopsis, medication cost effectiveness and economic burden.

Authors:  Tracy L Skaer
Journal:  Pharmacoeconomics       Date:  2014-05       Impact factor: 4.981

3.  Individuals with fibromyalgia and depression: findings from a nationally representative Canadian survey.

Authors:  Esme Fuller-Thomson; Jodie Nimigon-Young; Sarah Brennenstuhl
Journal:  Rheumatol Int       Date:  2011-01-08       Impact factor: 2.631

Review 4.  Societal and patient burden of fibromyalgia syndrome.

Authors:  Lieven Annemans; Katell Le Lay; Charles Taïeb
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

5.  2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary.

Authors:  Mary-Ann Fitzcharles; Peter A Ste-Marie; Don L Goldenberg; John X Pereira; Susan Abbey; Manon Choinière; Gordon Ko; Dwight E Moulin; Pantelis Panopalis; Johanne Proulx; Yoram Shir
Journal:  Pain Res Manag       Date:  2013 May-Jun       Impact factor: 3.037

6.  Use of complementary and alternative medicine providers by fibromyalgia patients under insurance coverage.

Authors:  Bonnie K Lind; William E Lafferty; Patrick Timothy Tyree; Paula K Diehr; David E Grembowski
Journal:  Arthritis Rheum       Date:  2007-02-15

Review 7.  [Influence of depression on fibromyalgia : A systematic review].

Authors:  M Lange; F Petermann
Journal:  Schmerz       Date:  2010-08       Impact factor: 1.107

8.  [Aims of the guidelines for diagnostic and treatment of fibromyalgia syndrome].

Authors:  M Schiltenwolf; W Eich; R Schmale-Grete; W Häuser
Journal:  Schmerz       Date:  2008-06       Impact factor: 1.107

9.  Epidemiology, costs, and the economic burden of fibromyalgia.

Authors:  Michael Spaeth
Journal:  Arthritis Res Ther       Date:  2009-06-30       Impact factor: 5.156

10.  Health costs in patients treated for depression, in patients with depressive symptoms treated for another chronic disorder, and in non-depressed patients: a two-year prospective cohort study in anthroposophic outpatient settings.

Authors:  Harald J Hamre; Claudia M Witt; Anja Glockmann; Renatus Ziegler; Gunver S Kienle; Stefan N Willich; Helmut Kiene
Journal:  Eur J Health Econ       Date:  2010-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.